HOOK vs. MIST, QTTB, ACRS, ETON, RVPH, ASRT, VTVT, CMRX, ONCY, and GNLX
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Milestone Pharmaceuticals (MIST), Q32 Bio (QTTB), Aclaris Therapeutics (ACRS), Eton Pharmaceuticals (ETON), Reviva Pharmaceuticals (RVPH), Assertio (ASRT), vTv Therapeutics (VTVT), Chimerix (CMRX), Oncolytics Biotech (ONCY), and Genelux (GNLX). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
Hookipa Pharma received 10 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. Likewise, 69.11% of users gave Hookipa Pharma an outperform vote while only 67.57% of users gave Milestone Pharmaceuticals an outperform vote.
Milestone Pharmaceuticals has higher earnings, but lower revenue than Hookipa Pharma. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Milestone Pharmaceuticals' net margin of -405.28%. Milestone Pharmaceuticals' return on equity of -72.30% beat Hookipa Pharma's return on equity.
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 10.4% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 1 articles in the media. Hookipa Pharma's average media sentiment score of 1.61 beat Milestone Pharmaceuticals' score of 1.40 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.
Milestone Pharmaceuticals has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
Milestone Pharmaceuticals presently has a consensus target price of $10.75, indicating a potential upside of 521.39%. Hookipa Pharma has a consensus target price of $4.67, indicating a potential upside of 489.97%. Given Hookipa Pharma's higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Hookipa Pharma.
Summary
Milestone Pharmaceuticals and Hookipa Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
